Moderna Teams Up With Chinese Biotech To Assess Cell-Based Therapy And Cancer Vaccine Combo
Portfolio Pulse from Vandana Singh
Moderna Inc (NASDAQ:MRNA) and Chinese biotech CARsgen Therapeutics have partnered to investigate a combination of CARsgen's investigational Claudin18.2 CAR T-cell product candidate (CT041) and Moderna's investigational Claudin18.2 mRNA cancer vaccine. The collaboration will involve preclinical studies and a phase 1 clinical trial. Moderna has previously collaborated with Merck & Co Inc (NYSE:MRK) on an mRNA cancer vaccine that showed promising results.
August 21, 2023 | 3:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna partners with CARsgen Therapeutics to investigate a combination of investigational cancer treatments.
The collaboration with CARsgen Therapeutics to investigate a combination of investigational cancer treatments could potentially lead to new product developments and revenue streams for Moderna. This is likely to have a positive impact on Moderna's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Moderna has previously collaborated with Merck on an mRNA cancer vaccine that showed promising results.
The mention of Merck in the article is in relation to a past collaboration with Moderna. While the results of this collaboration were positive, the news does not provide new information that would likely impact Merck's stock in the short term.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50